Iron chelation therapy in aceruloplasminaemia: Study of a patient with a novel missense mutation

Gut

Volumn 53, Issue 5, 2004, Pages 756-758

  Mariani, R ^a   Arosio, C ^a   Pelucchi, S ^a   Grisoli, M ^b   Piga, A ^c   Trombini, P ^a   Piperno, A ^a,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CERULOPLASMIN; DEFERIPRONE; FERRITIN; IRON CHELATING AGENT; PHENYLALANINE; TRANSFERRIN;

ACERULOPLASMINEMIA; ADULT; ANEMIA; ARTICLE; BRAIN; CASE REPORT; CHELATION THERAPY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG MECHANISM; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; IMAGING SYSTEM; IRON BLOOD LEVEL; IRON OVERLOAD; MISSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN SATURATION; PRIORITY JOURNAL; PROBABILITY;

ADULT; CERULOPLASMIN; CHELATION THERAPY; DEFEROXAMINE; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MUTATION, MISSENSE; PEDIGREE; PYRIDONES;

EID: 2342434172     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.030429     Document Type: Article

References (15)

1. Mukhopadhayay CK, Attieh ZK, Fox PL. Role of ceruloplasmin in cellular iron uptake. Science 1998;279:714-17.
2. Harris ZL, Durley AP, Man TK, et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci U S A 1999;96:10812-17.
3. Nittis T, Gitlin JD. The copper-iron connection: hereditary aceruloplasminemia. Semin Hematol 2002;39:282-9.
4. Yonekawa M, Okabe T, Asamoto Y, et al. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur Neurol 1999;42:157-62.
5. Morita H, Ikeda S, Yamamoto K, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study or a Japanese family. Ann Neurol 1995;37:646-56.
6. Bosio S, De Gobbi M, Roetto A, et al. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 2002;100:2246-8.
7. Lorèal O, Turlin B, Pigeon C, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 2002;36:851-6.
8. Helman NE, Schafer M, Gehrke S, et al. Hepatic iron overload in aceruloplasminemia. Gut 2000;47:858-60.
9. Miyajima H, Takahashi Y, Kamats T, et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997;41:404-7.
10. Beutler EA, Hoffbrand VA, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program), 2003:40-61.
11. Brittenham GM, Forrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-5.
12. Lee PL, Gelbart T, West C, et al. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chain, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cell Mol Dis 2001;27:783-802.
13. Hellman NE, Kono S, Miyajima H, et al. Biochemical analysis of a missense mutation in aceruloplasminemia. J Biol Chem 2002;277:1375-80.
14. Daiman M, Morial S, Susa A, et al. Hypocaeruloplasminemia with heteroallelic caeruloplasmin gene mutation: MRI of the brain. Neuroradiology 1999;41:185-7.
15. Miyajima H, Kono S, Takahashi Y, et al. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 2001;57:2205-10.